- Home
- VLYPO vs TGTX Comparison
VLYPO vs TGTX Comparison
Compare VLYPO & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLYPO
- TGTX
- Stock Information
- Founded
- VLYPO N/A
- TGTX 1993
- Country
- VLYPO United States
- TGTX United States
- Employees
- VLYPO 3732
- TGTX N/A
- Industry
- VLYPO Major Banks
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- VLYPO Finance
- TGTX Health Care
- Exchange
- VLYPO Nasdaq
- TGTX Nasdaq
- Market Cap
- VLYPO N/A
- TGTX 4.2B
- IPO Year
- VLYPO N/A
- TGTX 1995
- Fundamental
- Price
- VLYPO $25.08
- TGTX $32.51
- Analyst Decision
- VLYPO
- TGTX Strong Buy
- Analyst Count
- VLYPO 0
- TGTX 4
- Target Price
- VLYPO N/A
- TGTX $42.50
- AVG Volume (30 Days)
- VLYPO N/A
- TGTX 2.0M
- Earning Date
- VLYPO N/A
- TGTX 11-03-2025
- Dividend Yield
- VLYPO N/A
- TGTX N/A
- EPS Growth
- VLYPO N/A
- TGTX N/A
- EPS
- VLYPO N/A
- TGTX 0.36
- Revenue
- VLYPO N/A
- TGTX $454,069,000.00
- Revenue This Year
- VLYPO N/A
- TGTX $82.58
- Revenue Next Year
- VLYPO N/A
- TGTX $44.99
- P/E Ratio
- VLYPO N/A
- TGTX $88.20
- Revenue Growth
- VLYPO N/A
- TGTX 30.96
- 52 Week Low
- VLYPO N/A
- TGTX $21.16
- 52 Week High
- VLYPO N/A
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- VLYPO 44.45
- TGTX 60.17
- Support Level
- VLYPO $24.99
- TGTX $31.29
- Resistance Level
- VLYPO $25.17
- TGTX $32.56
- Average True Range (ATR)
- VLYPO 0.24
- TGTX 1.15
- MACD
- VLYPO -0.03
- TGTX 0.36
- Stochastic Oscillator
- VLYPO 31.17
- TGTX 85.57
About VLYPO Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.